Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 8/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.74 |
| ▸ | USP2 | O75604 | 3/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.74 |
| ▸ | CASP7 | P55210 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | RAD52 | P43351 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12721650 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL4084552 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL4084628 | 0.88 | CYP1A2 (0.78) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL1084053 | 0.85 | MEN1 (1.00) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL31612794 | 0.85 | MEN1 (1.00) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL1083950 | 0.85 | CYP3A4 (0.74) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL4084986 | 0.85 | ABCB1 (0.78) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL4085036 | 0.85 | CYP1A2 (1.00) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL1084026 | 0.85 | HIF1A (0.76) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 | |
| SCHEMBL6125247 | 0.83 | TSHR (0.84) | CYP1A2CYP3A4CYP2D6ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | CYP1A2 2477/4885CYP3A4 2113/4885CYP2D6 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.